Ring-Substituted 1-Hydroxynaphthalene-2-Carboxanilides Inhibit Proliferation and Trigger Mitochondria-Mediated Apoptosis

Ring-substituted 1-hydroxynaphthalene-2-carboxanilides were previously investigated for their antimycobacterial properties. In our study, we have shown their antiproliferative and cell death-inducing effects in cancer cell lines. Cell proliferation and viability were assessed by WST-1 assay and a dye exclusion test, respectively. Cell cycle distribution, phosphatidylserine externalization, levels of reactive oxygen or nitrogen species (RONS), mitochondrial membrane depolarization, and release of cytochrome c were estimated by flow cytometry. Levels of regulatory proteins were determined by Western blotting. Our data suggest that the ability to inhibit the proliferation of THP-1 or MCF-7 cells might be referred to meta- or para-substituted derivatives with electron-withdrawing groups -F, -Br, or -CF3 at anilide moiety. This effect was accompanied by accumulation of cells in G1 phase. Compound 10 also induced apoptosis in THP-1 cells in association with a loss of mitochondrial membrane potential and production of mitochondrial superoxide. Our study provides a new insight into the action of salicylanilide derivatives, hydroxynaphthalene carboxamides, in cancer cells. Thus, their structure merits further investigation as a model moiety of new small-molecule compounds with potential anticancer properties.

[1]  R. Enriz,et al.  Searching new structural scaffolds for BRAF inhibitors. An integrative study using theoretical and experimental techniques. , 2019, Bioorganic chemistry.

[2]  A. Bąk,et al.  Design and synthesis of anticancer 1-hydroxynaphthalene-2-carboxanilides with a p53 independent mechanism of action , 2019, Scientific Reports.

[3]  Hsu-Shan Huang,et al.  A new niclosamide derivatives‐B17 can inhibit urological cancers growth through apoptosis‐related pathway , 2018, Cancer medicine.

[4]  R. Musioł An overview of quinoline as a privileged scaffold in cancer drug discovery , 2017, Expert opinion on drug discovery.

[5]  Yanli Jin,et al.  The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo , 2017, Theranostics.

[6]  Sen Chen,et al.  Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/β-catenin and inducing mitochondrial dysfunctions , 2016, SpringerPlus.

[7]  Š. Pospíšilová,et al.  N-Alkoxyphenylhydroxynaphthalenecarboxamides and Their Antimycobacterial Activity , 2016, Molecules.

[8]  J. Jampílek,et al.  Antiproliferative and Pro-Apoptotic Effect of Novel Nitro-Substituted Hydroxynaphthanilides on Human Cancer Cell Lines , 2016, International journal of molecular sciences.

[9]  S. Koenig,et al.  The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway. , 2016, The Journal of surgical research.

[10]  Y. Assaraf,et al.  Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new targets. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[11]  Hua Gao,et al.  Synthesis of p‐O‐Alkyl Salicylanilide Derivatives as Novel EGFR Inhibitors , 2016, Drug development research.

[12]  Mark A Feitelson,et al.  Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. , 2015, Seminars in cancer biology.

[13]  J. Férriz,et al.  Salicylanilide carbamates: Promising antibacterial agents with high in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA). , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  X. Ren,et al.  Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure. , 2015, Bioorganic & medicinal chemistry.

[15]  M. Clausen,et al.  FDA-approved small-molecule kinase inhibitors. , 2015, Trends in pharmacological sciences.

[16]  A. Coffey,et al.  Synthesis and Biological Evaluation of N-Alkoxyphenyl-3-hydroxynaphthalene-2-carboxanilides , 2015, Molecules.

[17]  Javier León,et al.  Myc and cell cycle control. , 2015, Biochimica et biophysica acta.

[18]  I. Kushkevych,et al.  Synthesis and antimycobacterial properties of ring-substituted 6-hydroxynaphthalene-2-carboxanilides. , 2015, Bioorganic & medicinal chemistry.

[19]  R. Roskoski,et al.  Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. , 2015, Pharmacological research.

[20]  Patrycja Nowak-Sliwinska,et al.  The chicken chorioallantoic membrane model in biology, medicine and bioengineering , 2014, Angiogenesis.

[21]  Donald J Buchsbaum,et al.  Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. , 2014, Cancer letters.

[22]  Yuquan Wei,et al.  The Anthelmintic Drug Niclosamide Induces Apoptosis, Impairs Metastasis and Reduces Immunosuppressive Cells in Breast Cancer Model , 2014, PloS one.

[23]  J. Jampílek,et al.  Antimycobacterial and herbicidal activity of ring-substituted 1-hydroxynaphthalene-2-carboxanilides. , 2013, Bioorganic & medicinal chemistry.

[24]  W. Curran,et al.  Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer , 2013, PloS one.

[25]  R. Fimmers,et al.  Anticancer Effects of Niclosamide in Human Glioblastoma , 2013, Clinical Cancer Research.

[26]  A. Coffey,et al.  Antibacterial and Herbicidal Activity of Ring-Substituted 2-Hydroxynaphthalene-1-carboxanilides , 2013, Molecules.

[27]  A. Coffey,et al.  Antibacterial and Herbicidal Activity of Ring-Substituted 2-Hydroxynaphthalene-1-carboxanilides , 2013, Molecules.

[28]  Q. Shen,et al.  Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents. , 2013, ACS medicinal chemistry letters.

[29]  V. Buchta,et al.  In vitro antibacterial and antifungal activity of salicylanilide pyrazine-2-carboxylates. , 2012, Medicinal chemistry (Shariqah (United Arab Emirates)).

[30]  Hans Clevers,et al.  Wnt/β-Catenin Signaling and Disease , 2012, Cell.

[31]  N. Sonenberg,et al.  Structure-Activity Analysis of Niclosamide Reveals Potential Role for Cytoplasmic pH in Control of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling* , 2012, The Journal of Biological Chemistry.

[32]  F. Dick,et al.  The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle , 2012, Cell Division.

[33]  G. Piazza,et al.  Niclosamide Suppresses Cancer Cell Growth By Inducing Wnt Co-Receptor LRP6 Degradation and Inhibiting the Wnt/β-Catenin Pathway , 2011, PloS one.

[34]  M. Krátký,et al.  Salicylanilide ester prodrugs as potential antimicrobial agents--a review. , 2011, Current pharmaceutical design.

[35]  F. Khanim,et al.  Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production , 2011, Blood cancer journal.

[36]  A. Imramovský,et al.  Salicylanilides and Their Derivatives as Perspective Antituberculosis Drugs: Synthetic Routes and Biological Evaluations , 2011 .

[37]  P. Beroza,et al.  Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG). , 2011, Journal of medicinal chemistry.

[38]  J. Hwang,et al.  Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death. , 2011, BMB reports.

[39]  A. Imramovský,et al.  Salicylanilides and Their Derivates as Perspective Anti-tuberculosis Drugs: Synthetic Routes and Biological Evaluations , 2011 .

[40]  A. Hampl,et al.  Geranylated flavanone tomentodiplacone B inhibits proliferation of human monocytic leukaemia (THP‐1) cells , 2011, British journal of pharmacology.

[41]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[42]  Qiang He,et al.  Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. , 2010, ACS medicinal chemistry letters.

[43]  J. Dancey mTOR signaling and drug development in cancer , 2010, Nature Reviews Clinical Oncology.

[44]  Yanli Jin,et al.  Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. , 2010, Cancer research.

[45]  X. Ren,et al.  The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. , 2009, Biochemistry.

[46]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[47]  J. Turkson,et al.  STAT3 as a target for inducing apoptosis in solid and hematological tumors , 2008, Cell Research.

[48]  Qiu-Ju Jiang,et al.  Anion-triggered substituent-dependent conformational switching of salicylanilides. New hints for understanding the inhibitory mechanism of salicylanilides. , 2007, The Journal of organic chemistry.

[49]  Elisa Nemes,et al.  Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry , 2007, Nature Protocols.

[50]  A. Giordano,et al.  RB and cell cycle progression , 2006, Oncogene.

[51]  E. Haura SRC and STAT pathways. , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[52]  W. Gerald,et al.  Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. , 2006, Cancer research.

[53]  Dajun Yang,et al.  SUCI02 inhibits the erbB‐2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells , 2006, Cancer science.

[54]  Arnaud M. Vigneron,et al.  The STAT3 Transcription Factor Is a Target for the Myc and Riboblastoma Proteins on the Cdc25A Promoter* , 2005, Journal of Biological Chemistry.

[55]  P. Furet,et al.  Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor. , 2004, European journal of medicinal chemistry.

[56]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[57]  C. Thompson,et al.  Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis , 2003, Cell Death and Differentiation.

[58]  J. Pietenpol,et al.  Cell-cycle dysregulation and anticancer therapy. , 2003, Trends in pharmacological sciences.

[59]  J. Kuneš,et al.  Relationship between the Structure and Antimycobacterial Activity of Substituted Salicylanilides , 2003, Archiv der Pharmazie.

[60]  Y. Urano,et al.  Development of Novel Fluorescence Probes That Can Reliably Detect Reactive Oxygen Species and Distinguish Specific Species* 210 , 2003, The Journal of Biological Chemistry.

[61]  D. Ferrari,et al.  Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. , 2002, Molecular biology of the cell.

[62]  Martin Schuler,et al.  Cytochrome C Maintains Mitochondrial Transmembrane Potential and Atp Generation after Outer Mitochondrial Membrane Permeabilization during the Apoptotic Process , 2001, The Journal of cell biology.

[63]  G. Swan The pharmacology of halogenated salicylanilides and their anthelmintic use in animals. , 1999, Journal of the South African Veterinary Association.

[64]  R. Kanojia,et al.  Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria. , 1998, Journal of medicinal chemistry.

[65]  R. Benz,et al.  The molecular mechanism of action of the proton ionophore FCCP (carbonylcyanide p-trifluoromethoxyphenylhydrazone). , 1983, Biophysical journal.

[66]  R. Metcalf,et al.  Salicylanilides: A New Group of Active Uncouplers of Oxidative Phosphorylation , 1967, Science.

[67]  G. C. Walker,et al.  Antifungal action of salicylanilide. II. , 1960, Canadian journal of biochemistry and physiology.

[68]  D. Karnofsky,et al.  Growth of transplantable human tumors in the chick embryo and hatched chick. , 1956, Cancer research.

[69]  R. Pathak,et al.  The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research. , 2018, American journal of cancer research.

[70]  J. Trapani,et al.  Assaying cytochrome C translocation during apoptosis. , 2004, Methods in molecular biology.

[71]  H. Wolf‐Watz,et al.  Salicylanilides are potent inhibitors of type III secretion in Yersinia. , 2003, Advances in experimental medicine and biology.